A Randomised, Double-blind, Placebo-Controlled, Two-way Cross-over, Single Centre Study in Healthy Subjects to Assess the Effect of Oral Dosing of AZD5069 on Neutrophil Number and Function in Peripheral Blood and the Ability to Recruit Neutrophils Into the Circulation After Exercise and Subcutaneous.

Trial Profile

A Randomised, Double-blind, Placebo-Controlled, Two-way Cross-over, Single Centre Study in Healthy Subjects to Assess the Effect of Oral Dosing of AZD5069 on Neutrophil Number and Function in Peripheral Blood and the Ability to Recruit Neutrophils Into the Circulation After Exercise and Subcutaneous.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2015

At a glance

  • Drugs AZD 5069 (Primary)
  • Indications Bronchiectasis; Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Aug 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
    • 31 Jul 2012 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 17 Jan 2012 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top